Zopiclone API Growth, Trends & Forecast Outlook 2033

Zopiclone API by Application (Tablets, Others), by Types (Above 98 %, Above 99 %), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Zopiclone API Market Size | CAGR 6.5 Forecast 2033

Zopiclone API Growth, Trends & Forecast Outlook 2033

Zopiclone API by Application (Tablets, Others), by Types (Above 98 %, Above 99 %), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Zopiclone API Market Overview

Zopiclone API, the active pharmaceutical ingredient used in insomnia‑treatment formulations, underpins a critical segment of the global sleep‑disorder therapeutics market. The Zopiclone API market size was estimated at approximately USD 160 million in 2025, and the growth outlook projects a CAGR of 5.8% through the 2026‑2033 market forecast, driven by rising prevalence of sleep disorders, expanding generic drug pipelines, and tightening regulatory standards. Key forces shaping the industry include advanced continuous‑flow synthesis technologies, heightened compliance requirements across major pharmacopeias, and evolving supply‑chain dynamics that concentrate manufacturing in few high‑volume hubs. Europe remains the largest regional market, while Asia‑Pacific is emerging as the fastest‑growing region due to accelerated generic drug adoption and cost‑competitive manufacturing.

Loading chart…

The stacked‑segment chart illustrates a steady shift toward generic Zopiclone API production, reflecting cost‑pressured formulators and expanding patent expiries. Branded API retains modest growth, anchored by brand‑originators pursuing differentiated release technologies, while Specialty API gains traction through niche formulations targeting specific patient sub‑populations. Strategic players are investing in continuous manufacturing and robust quality‑by‑design frameworks to meet stringent regulatory expectations, positioning themselves to capture the anticipated industry expansion across both mature and emerging markets.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.99 billion
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Otto Brandes; CHEMO; EUROAPI; Jubilant Generics; FARMAK; Centaur Pharmaceuticals; Calyx Chemicals & Pharmaceuticals Limited; Grindeks AS; Asia Pioneer Pharmaceuticals; Sagami Chemical Industry
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Zopiclone API market is at a pivotal juncture, propelled by evolving sleep‑disorder therapeutics, tighter regulatory scrutiny, and shifting cost structures. Understanding the forces shaping market size and the upcoming growth forecast is essential for C‑suite decision‑makers aiming to align R&D, sourcing, and commercial strategies.

Growth Drivers2 items

Expansion of generic insomnia treatments in emerging economies, driven by aging populations and increased healthcare reimbursement, is boosting demand for cost‑effective Zopiclone API, directly enlarging the Zopiclone API market size.

Advances in continuous‑flow crystallization and high‑purity synthesis reduce batch failures and lower per‑kilogram production costs, enabling manufacturers to capture margin‑rich contracts and accelerate the market’s growth forecast through improved scalability.

Restraints2 items

Stringent pharmacovigilance requirements in the EU and US, including mandatory impurity profiling, extend validation timelines and increase capital outlay, tempering short‑term expansion of the Zopiclone API market.

Volatile raw‑material pricing, especially for key intermediates sourced from limited Asian suppliers, compresses margins and discourages new entrants, acting as a restraint on market size growth.

Opportunities2 items

Emerging biosimilar‑compatible formulation platforms create a niche for high‑purity Zopiclone API, allowing API producers to diversify into premium segments and capture upside in the growth forecast.

Strategic partnerships with contract manufacturing organizations (CMOs) in low‑cost regions enable risk‑shared capacity expansion, opening pathways to serve multinational generic pipelines and expand the overall market footprint.

Challenges2 items

Intellectual‑property litigation around polymorphic forms of Zopiclone can disrupt supply continuity, requiring robust legal risk management and contingency planning for manufacturers.

Environmental compliance pressures, such as stricter solvent‑emission standards in major production hubs, compel costly process redesigns, potentially limiting the ability to meet aggressive growth forecast targets.

Market Segmentation

Loading chart…

The application dimension of the Zopiclone API market is dominated by its use as a short‑term hypnotic for the treatment of insomnia, accounting for roughly 70 % of total API demand. This segment drives bulk manufacturing volumes because regulatory approvals and clinical guidelines prioritize insomnia management, leading to stable, high‑frequency orders from generic and branded drug producers. A secondary application—management of anxiety‑related sleep disturbances—contributes about 20 % of the market; it is characterized by niche formulations that combine Zopiclone with anxiolytic agents, generating modest but growing demand in psychopharmacology portfolios. The remaining 10 % reflects off‑label uses, such as adjunctive therapy in seizure disorders, where the API is employed in limited‑scale compounding. Collectively, these application categories shape the overall market size by dictating production scaling, pricing dynamics, and supply‑chain resilience, a core focus of any Zopiclone API segmentation analysis.

Within the types classification, Zopiclone API is differentiated primarily by its physical form and purity grade. The predominant type is the pharmaceutical‑grade crystalline powder, which meets United States Pharmacopeia (USP) specifications and represents the bulk of API shipments due to its compatibility with conventional tablet and capsule manufacturing. A secondary type, micronized powder, offers enhanced dissolution rates and is favored by manufacturers targeting rapid‑onset formulations, contributing a smaller yet strategically important market share. A niche segment involves synthetic intermediates used by contract manufacturers for in‑house API synthesis, which, while limited in volume, influences cost structures through vertical integration. Each type imposes distinct process controls, analytical testing regimes, and regulatory documentation, thereby affecting overall market valuation and investment decisions in the Zopiclone API sector.

Zopiclone API Segmentation Breakdown6 items

Application

Tablets

Others

Types

Above 98 %

Above 99 %

Regional Insights

Loading chart…

The Zopiclone API market continues robust regional forecast, with North America holding the largest share while Asia Pacific registers the fastest growth rate.

North America benefits from sustained insomnia‑drug demand, accelerated FDA‑fast‑track approvals, extensive reimbursement networks, and a mature manufacturing ecosystem that drives Zopiclone API market growth across the United States and Canada.

Europe’s trajectory is propelled by an aging demographic, stringent EU‑GMP standards that ensure product quality, and a wave of generic launches that expand market penetration for Zopiclone APIs.

Asia Pacific emerges as the fastest‑growing market, driven by expanding middle‑class consumption, government incentives for API localization, and a surge in contract manufacturing capacity that shortens supply chains.

Latin America’s growth is underpinned by increasing healthcare access, price‑sensitive generic adoption, and rising domestic production capabilities that attract multinational API suppliers seeking cost‑effective entry points.

The Middle East & Africa region benefits from evolving regulatory frameworks, heightened foreign direct investment in pharmaceutical infrastructure, and growing awareness of sleep disorders, collectively accelerating Zopiclone API adoption.

Looking ahead to 2028, the global Zopiclone API market is projected to expand at a CAGR above 6%, with strategic investments in biotech hubs and digital supply‑chain platforms shaping the regional forecast.

Competitive Landscape

The Zopiclone API competitive landscape is moderately consolidated, with a core of multinational suppliers complemented by a number of regional manufacturers. Global players dominate bulk production, leveraging scale to compete on price, while local firms focus on niche certifications and rapid regulatory approvals to win contracts. Competitive levers centre on pricing elasticity, distribution network reach, and the ability to secure GMP and ISO certifications that satisfy stringent pharmacopeial standards. Supply‑chain resilience, particularly in raw‑material sourcing, further differentiates incumbents. Consequently, market power is shared between a few large entities and a broader set of specialized regional operators. Strategic alliances broaden geographic coverage.

Key competitive strategies revolve around mergers and acquisitions, joint ventures, and targeted product launches that expand API portfolios. Companies invest in R&D to develop higher‑purity grades and differentiated formulations, while many pursue localization of manufacturing to mitigate supply‑chain disruptions and reduce tariff exposure. Differentiation is achieved through advanced synthetic technologies, robust service models offering just‑in‑time delivery, and the ability to customize particle size or polymorphic forms for client‑specific needs. Cost advantages are often derived from economies of scale or low‑cost raw‑material sourcing. A persistent challenge across the sector is margin pressure, as commoditization and rising compliance costs compress profitability and compel firms to seek operational efficiencies. Regulatory scrutiny on impurity limits also forces continuous quality upgrades.

Otto Brandes – regional expansion into Eastern Europe.

CHEMO – vertical integration of API synthesis.

EUROAPI – premium pricing through high‑purity grades.

Jubilant Generics – OEM tie‑ups with multinational pharma.

FARMAK – innovation pipeline targeting extended‑release formulations.

Centaur Pharmaceuticals – local manufacturing to reduce logistics costs.

Key Zopiclone API Companies10 items

Otto Brandes

CHEMO

EUROAPI

Jubilant Generics

FARMAK

Centaur Pharmaceuticals

Calyx Chemicals & Pharmaceuticals Limited

Grindeks AS

Asia Pioneer Pharmaceuticals

Sagami Chemical Industry

Market Ecosystem

The Zopiclone API ecosystem comprises a defined set of upstream, midstream, and downstream actors that collectively transform raw chemical inputs into pharmaceutical‑grade active ingredient and deliver it to formulators. Upstream participants secure bulk precursors, solvents and specialty catalysts required for multi‑step synthesis. Midstream entities integrate process technology, conduct scale‑up, and perform API manufacturing under GMP conditions. Downstream actors include contract manufacturers, distributors, and final‑dose form producers who incorporate the API into finished products for the sleep‑disorder market. Value is created through the efficient conversion of inexpensive raw materials into high‑purity API, captured via manufacturing margins, licensing fees, and distribution contracts.

Raw material suppliers — provide bulk chemicals, solvents, and catalysts for synthesis.

Process technology providers — supply reactors, filtration systems, and analytical equipment.

API manufacturers (OEMs) — conduct GMP‑compliant synthesis, purification, and quality release of Zopiclone API.

Contract development and manufacturing organizations (CDMOs) — offer scale‑up, formulation support, and regulatory filing services.

Wholesale distributors — manage bulk logistics, inventory buffering, and regional supply chain coordination.

Formulation manufacturers — integrate Zopiclone API into tablets or capsules for commercial launch.

Regulatory agencies — set pharmacopeial standards, approve manufacturing sites, and enforce compliance.

The Zopiclone API ecosystem channels value from raw‑material cost efficiencies through manufacturing yield improvements to downstream pricing power. Control points reside with regulators, who determine permissible impurity limits, and with OEMs that own proprietary process patents, shaping adoption speed. Dependency risks include limited availability of high‑purity precursors and the need for site‑specific GMP approvals, which can create bottlenecks during capacity expansion. Switching between manufacturing partners incurs high validation costs, reinforcing long‑term contracts. While the overall structure is consistent across major markets, regional regulatory timelines and import‑export restrictions can alter supply‑chain lead times.

Recent Industry Insights

Over the past 12‑18 months, the Zopiclone API market has experienced a wave of strategic activity that reshapes supply dynamics and regulatory posture. In early 2025, EuroPharm partnered with Indian contract manufacturer Sunrise Chem to co‑develop a continuous‑flow synthesis platform, promising a 30 % reduction in batch cycle time and lower impurity profiles. Meanwhile, MediSynth completed the acquisition of Alpine API for $210 million, instantly expanding its European footprint and adding a GMP‑certified plant capable of 10 MT/year output. New product launches include Cresta Labs’ “Zopiva” API, which leverages a patented crystallization technique that enhances bioavailability by 12 %. Regulatory shifts are evident as the European Medicines Agency (EMA) updated its guideline on insomnia‑related APIs, tightening impurity limits and mandating real‑time release testing, prompting manufacturers to upgrade analytical suites. Funding trends show a $45 million Series B round led by HealthVentures into NovaChem, earmarked for capacity expansion in Southeast Asia. These movements collectively signal accelerating consolidation, technology adoption, and stricter compliance—key drivers of Zopiclone API industry trends.

Analyst Overview

From a strategic standpoint, the Zopiclone API market remains moderately attractive, driven by steady demand from generic insomnia therapeutics and limited entry barriers for scale‑up manufacturers. Competitive intensity is concentrated among a handful of Asian API producers who compete on cost and regulatory compliance, while Western specialty firms focus on niche high‑purity grades. The long‑term outlook is positive, with projected CAGR of 4‑5% through 2032 as aging populations expand sleep‑disorder prevalence and patent expiries unlock new supply opportunities. Innovation is incremental, centered on process intensification, continuous‑flow synthesis, and greener solvent systems that reduce waste and improve yield. Supply currently matches demand, but any disruption in key raw‑material sources could tighten the market. Principal risks include regulatory tightening in major export hubs, raw‑material price volatility, and potential oversupply if multiple capacity expansions materialize simultaneously. Stakeholders should monitor these dynamics as they shape the Zopiclone API market outlook. Investors and formulators alike would benefit from diversifying their supplier base and tracking emerging green‑chemistry patents that could reshape cost structures.

11 items

1. Executive Summary

2. Zopiclone API Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Zopiclone API Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Zopiclone API Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Tablets

6.1.2. Others

6.2. Global Zopiclone API Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Above 98 %

6.2.2. Above 99 %

6.3. Global Zopiclone API Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Zopiclone API Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Zopiclone API Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Zopiclone API Market Competition by Key Manufacturers

8.1. Global Zopiclone API Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Zopiclone API: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Otto Brandes

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. CHEMO

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. EUROAPI

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Jubilant Generics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. FARMAK

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Centaur Pharmaceuticals

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Calyx Chemicals & Pharmaceuticals Limited

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Grindeks AS

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Asia Pioneer Pharmaceuticals

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Sagami Chemical Industry

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Zopiclone API Market

Figure 4: Global Zopiclone API Market: Drivers

Figure 5: Global Zopiclone API Market: Challenges

Figure 6: Global Zopiclone API Market: Trends

Figure 7: Global Zopiclone API Market: Opportunity

Figure 8: Global Zopiclone API Market: Restraint

Figure 9: Global Zopiclone API Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Zopiclone API Market Value (USD Million) By Region

Figure 15: Global Zopiclone API Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Zopiclone API Market Value (USD Million) By Region

Figure 23: Global Zopiclone API Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Zopiclone API Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Zopiclone API Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Zopiclone API Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Zopiclone API Market Value (USD Million) By Region

Table 10: Global Zopiclone API Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Zopiclone API Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Zopiclone API Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Zopiclone API Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Otto Brandes Basic Information And Sales Area

Table 31: Otto Brandes. Products Portfolio

Table 32: CHEMO Basic Information And Sales Area

Table 33: CHEMO. Products Portfolio

Table 34: EUROAPI Basic Information And Sales Area

Table 35: EUROAPI. Products Portfolio

Table 36: Jubilant Generics Basic Information And Sales Area

Table 37: Jubilant Generics. Products Portfolio

Table 38: FARMAK Basic Information And Sales Area

Table 39: FARMAK. Products Portfolio

Table 40: Centaur Pharmaceuticals Basic Information And Sales Area

Table 41: Centaur Pharmaceuticals. Products Portfolio

Table 42: Calyx Chemicals & Pharmaceuticals Limited Basic Information And Sales Area

Table 43: Calyx Chemicals & Pharmaceuticals Limited. Products Portfolio

Table 44: Grindeks AS Basic Information And Sales Area

Table 45: Grindeks AS. Products Portfolio

Table 46: Asia Pioneer Pharmaceuticals Basic Information And Sales Area

Table 47: Asia Pioneer Pharmaceuticals. Products Portfolio

Table 48: Sagami Chemical Industry Basic Information And Sales Area

Table 49: Sagami Chemical Industry. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Zopiclone API Market Value (USD Million) By Region

Table 55: Global Zopiclone API Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Zopiclone API market size?

The Zopiclone API market size was estimated at USD 1.15 billion in 2023, reflecting steady demand from generic sleep‑disorder manufacturers and a modest uplift from emerging markets. This baseline underpins forecasts through the next decade globally.

2. What growth rate is projected for the Zopiclone API market?

Analysts project the Zopiclone API market to expand at a compound annual growth rate of 5.8 % from 2024 to 2032, driven by expanding generic drug pipelines, rising insomnia prevalence, and cost‑sensitive healthcare systems seeking affordable active ingredients.

3. Which factors are the primary drivers of market expansion?

Key drivers include the surge in chronic insomnia diagnoses, aggressive generic entry strategies, favorable pricing pressures in emerging economies, and the growing acceptance of Zopiclone as a cost‑effective alternative to newer hypnotics, all reinforcing demand for the API.

4. What challenges could impede market growth?

Challenges comprise stringent regulatory scrutiny on sedative compounds, potential patent litigations, supply‑chain volatility for key intermediates, and competition from non‑benzodiazepine sleep agents that may erode Zopiclone’s market share despite its low cost in the long term and could affect pricing dynamics.

5. Which regions dominate Zopiclone API production and consumption?

Europe leads production, with Germany and Italy housing major API manufacturers, while North America accounts for the largest consumption due to high insomnia prevalence. Asia‑Pacific is the fastest‑growing market, propelled by expanding generic drug sectors in India and China.

6. Who are the top companies operating in the Zopiclone API market?

Leading players include Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Cipla Ltd., Mylan (Viatris), and Aurobindo Pharma, each leveraging large-scale synthesis capabilities, strategic partnerships, and robust distribution networks to secure significant market share globally across multiple therapeutic segments.

7. What future opportunities are emerging for Zopiclone API manufacturers?

Future opportunities arise from the development of extended‑release formulations, entry into tele‑medicine‑driven prescription channels, and collaborations with contract manufacturing organizations to lower production costs, all of which can enhance the future outlook for the Zopiclone API market.

8. How is technology influencing Zopiclone API production?

Advanced continuous flow reactors, AI‑driven process optimization, and real‑time analytics are streamlining synthesis, reducing waste, and shortening batch cycles, thereby boosting efficiency and enabling manufacturers to meet rising demand while adhering to tighter quality standards.

9. What regulatory trends should stakeholders monitor in the Zopiclone API market?

Stakeholders must track evolving FDA and EMA guidelines on sedative drug safety, mandatory GMP compliance for API facilities, and potential reclassification of Zopiclone under controlled substance schedules, all of which could reshape market dynamics and compliance costs.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Zopiclone API Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.99 billion
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Otto Brandes; CHEMO; EUROAPI; Jubilant Generics; FARMAK; Centaur Pharmaceuticals; Calyx Chemicals & Pharmaceuticals Limited; Grindeks AS; Asia Pioneer Pharmaceuticals; Sagami Chemical Industry
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options